U.S. Subsidiary Of India’s Sun To Double Plant Size, Add Staff
This article was originally published in PharmAsia News
Sun Pharmaceuticals of India plans to double the size of the facilities of its U.S.-based subsidiary, Caraco Pharmaceuticals. Caraco, an independent arm of Sun, is based in Detroit where it plans a $22 million expansion and increase its staff over the next five years. Sun's U.S. arm markets 17 pharmaceuticals in the country, with another 27 in the pipeline for U.S. FDA approval. In addition, Caraco markets Sun's Indian products in the United States. (Click here for more
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.